TY - JOUR
T1 - Bisphosphonates in lung cancer
T2 - More than a palliative therapy?
AU - Jahanzeb, Mohammad
AU - Hirsh, Vera
N1 - Funding Information:
Publication of this article was supported by Novartis .
Funding Information:
M.J. has received grant/research support from Genentech BioOncology, Pfizer Inc, and Oxigene Inc . He has been a Speakers' Bureau participant for Genentech, sanofi-aventis US, Roche Pharmaceuticals, GlaxoSmithKline, Abraxis Pharmaceutical Products, and AstraZeneca. He has also served on Advisory Boards for Genentech, Eli Lilly and Company, Eisai Inc, AstraZeneca, Novartis Pharmaceuticals Corporation, Pfizer Inc, GlaxoSmithKline, Abraxis Pharmaceutical Products, sanofi-aventis US, Bayer Pharmaceuticals Corporation, Onyx Pharmaceuticals, Bristol-Myers Squibb Company, Oxigene Inc, and ImClone Systems. V.H. is a member of Novartis and Amgen advisory boards.
PY - 2010/6
Y1 - 2010/6
N2 - Bone metastases are a common complication in patients with advanced lung cancer, and most patients with bone metastases from lung cancer develop skeletal-related events (SREs). Skeletal-related events adversely impact patient quality of life and clinical outcome and are associated with increased costs of clinical management, underscoring the need for SRE prevention. Because current practice guidelines do not recommend pretreatment bone scans for all patients at initial presentation, skeletal involvement is not detected in a proportion of patients with early stage asymptomatic bone metastases. In addition, there are no uniform guidelines outlining treatment for patients with bone metastases. Although many bisphosphonates have not been investigated in this setting, zoledronic acid has proven efficacy in delaying the onset and reducing the risk of SREs in patients with bone metastases from lung cancer. Further, recent exploratory analyses in patients with bone metastases from solid tumors suggest that, in addition to normalizing biochemical markers of bone metabolism, zoledronic acid may improve survival in specific patient subsets, including those with lung cancer. Accordingly, several prospectively designed clinical trials assessing anticancer activity of zoledronic acid in the adjuvant setting are ongoing. New insights into the clinical relevance of bone-conserving therapy in patients with lung cancer are discussed.
AB - Bone metastases are a common complication in patients with advanced lung cancer, and most patients with bone metastases from lung cancer develop skeletal-related events (SREs). Skeletal-related events adversely impact patient quality of life and clinical outcome and are associated with increased costs of clinical management, underscoring the need for SRE prevention. Because current practice guidelines do not recommend pretreatment bone scans for all patients at initial presentation, skeletal involvement is not detected in a proportion of patients with early stage asymptomatic bone metastases. In addition, there are no uniform guidelines outlining treatment for patients with bone metastases. Although many bisphosphonates have not been investigated in this setting, zoledronic acid has proven efficacy in delaying the onset and reducing the risk of SREs in patients with bone metastases from lung cancer. Further, recent exploratory analyses in patients with bone metastases from solid tumors suggest that, in addition to normalizing biochemical markers of bone metabolism, zoledronic acid may improve survival in specific patient subsets, including those with lung cancer. Accordingly, several prospectively designed clinical trials assessing anticancer activity of zoledronic acid in the adjuvant setting are ongoing. New insights into the clinical relevance of bone-conserving therapy in patients with lung cancer are discussed.
UR - http://www.scopus.com/inward/record.url?scp=77955433435&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955433435&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2010.06.004
DO - 10.1053/j.seminoncol.2010.06.004
M3 - Article
C2 - 20682372
AN - SCOPUS:77955433435
VL - 37
SP - S45-S52
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - SUPPL.
ER -